Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Demeclocycline in mild to moderate COVID-19
jRCTs051200049Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of demeclocycline in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Change rate of CD8-positive T cells. Started Nov 2020; status: completed.
02
Drugs
demeclocycline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs051200049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200049.